CareDx Inc’s shares reached a 52-week high of $49.77 on Tuesday, closing at $49.69 with a market capitalization of $2.57 billion. The advance follows the release of strong second-quarter 2026 financial results.
The company reported adjusted earnings per share of $0.37, exceeding the analyst consensus of $0.23. Total revenue for the quarter totaled $132 million, up 52% year-over-year and surpassing the expected $113.82 million. Testing revenue, a key segment for CareDx, rose 61% to $99.9 million.
CareDx also raised its full-year guidance, reflecting confidence in its operational momentum. The stock’s 12-month performance stands at 283.22%, while its Piotroski Score of 9 indicates exceptional financial strength. The company maintains a neutral rating from H.C. Wainwright, which set a price target of $46.
